Tier 2 — strong

Effects of Quercetin Supplementation on Hematological Parameters in Non-Alcoholic Fatty Liver Disease: a Randomized, Double-Blind, Placebo-Controlled Pilot Study

Yahya Pasdar, Farhad Oubari, Mahin Nikougoftar Zarif, Mehrnaz Abbasi, Azizollah Pourmahmoudi, Mahboobe Hosseinikia
Clinical nutrition research 2020 9(1):11-19

Bibliography

PubMed
PMID 32095444
PubMed Central
PMC7015726
DOI
10.7762/cnr.2020.9.1.11
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
Reported disclosure: The authors declare that they have no competing interests.

Study snapshot

DesignRandomized double-blind placebo-controlled pilot trial
ModelHuman intervention research
Sample90 adults with fatty liver disease
InterventionTwice-daily quercetin capsules; the abstract's 500 mg dose wording needs full-method clarification
Duration12 weeks
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2020, this source examined cardiovascular and metabolic health. Design: Randomized double-blind placebo-controlled pilot trial. Sample/model: 90 adults with fatty liver disease. The exposure or intervention was Twice-daily quercetin capsules; the abstract's 500 mg dose wording needs full-method clarification. Follow-up or treatment period: 12 weeks.

Red-cell indices and ferritin differed from placebo, with changes in both directions across blood measures.

Hematological endpoints do not establish liver-fat, fibrosis or long-term clinical benefit. The exact daily dose needs source-method confirmation.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Red-cell indices and ferritin differed from placebo, with changes in both directions across blood measures.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: Twice-daily quercetin capsules; the abstract's 500 mg dose wording needs full-method clarification; 12 weeks.

What this study can and cannot tell us

  • Hematological endpoints do not establish liver-fat, fibrosis or long-term clinical benefit. The exact daily dose needs source-method confirmation.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetins efficacy on bone and inflammatory markers, body composition, and physical function in postmenopausal women
Alyssa R Bailly et al. · Journal of bone and mineral metabolism · 2025
Tier 2
Quercetin Reduces Vascular Senescence and Inflammation in Symptomatic Male but Not Female Coronary Artery Disease Patients
Pauline Mury et al. · Aging cell · 2025
Tier 2
Impact of quercetin in patients with myocardial infarction. A multicenter, randomized, and open-label pilot study
Sergey Kozhukhov et al. · Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese · 2024

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology